Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15109080 | 1.00 | TSHR (0.45) | TSHRLMNAALDH1A1HSD11B1CYP2A6 | |
| SCHEMBL15340796 | 0.83 | TSHR (0.39) | TSHRLMNAALDH1A1CYP2A6CYP1A2 | |
| SCHEMBL8664415 | 0.81 | HSD11B1 (0.46) | TSHRALDH1A1HSD11B1 | |
| 1,2-Dichlorobenzene SCHEMBL2922912 | 0.80 | TSHR (0.62) | TSHRLMNAALDH1A1HSD11B1CYP2A6 | |
| SCHEMBL5085586 | 0.78 | TSHR (0.50) | TSHRLMNAALDH1A1HSD11B1CYP2A6 | |
| SCHEMBL31568868 | 0.75 | TSHR (0.41) | TSHRLMNAALDH1A1CYP1A2 | |
| SCHEMBL24589026 | 0.75 | — | — | |
| SCHEMBL24758928 | 0.74 | CYP2A6 (0.46) | ALDH1A1CYP2A6CYP1A2 | |
| SCHEMBL19239131 | 0.74 | CYP1A2 (0.46) | TSHRLMNAALDH1A1CYP2A6CYP1A2 | |
| SCHEMBL9846801 | 0.74 | TSHR (0.45) | TSHRLMNAALDH1A1CYP2A6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4534528-A1 | NOVEL SULFANONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119685854-A | Catalyst for preparing sulfone, preparation method thereof and application of catalyst in preparing sulfone by electrocatalytic oxidation of sulfoxide | 齐鲁工业大学(山东省科学院) | 2025-03-25 | — | — | CN | disclosed |
| CN-119604487-A | Novel sulfimide derivative or pharmaceutically acceptable salt thereof and application thereof | 韩国科学技术研究院 | 2025-03-11 | — | — | CN | disclosed |
| CN-117486662-A | Method for synthesizing sulfoxide compound by heterogeneous catalysis | 成都理工大学 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022063190-A1 | PYRAZINE THIOBIPHENYL COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| EP-3883562-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceutials, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-5409893-A | Administering with platinum complexes | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-04-25 | — | — | US | disclosed |
| US-5385914-A | Cardiotonic carbostyril agents for treating heart ailments | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0355583-B1 | Cardiotonics | OTSUKA PHARMA CO LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0471709-B1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA (IT) | 1994-11-30 | — | — | EP | disclosed |
| US-5266577-A | Method of treating congestive heart failure using carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY LTD. (JP) | 1993-11-30 | — | — | US | disclosed |
| US-5198448-A | Cardiovascular disorders | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1993-03-30 | — | — | US | disclosed |
| EP-0471709-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS. | BOEHRINGER MANNHEIM ITALIA (IT) | 1992-02-26 | — | — | EP | disclosed |
| US-5053514-A | Side effect reduction; carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-10-01 | — | — | US | disclosed |
| WO-1990013553-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-11-15 | — | — | WO | disclosed |
| EP-0355583-A2 | Cardiotonics | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | RORB, RORC, RORA | TSHR 392/4885LMNA 3884/4885ALDH1A1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.